Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/Combined ACE inhibitor and ARB: no cardiovascular benefit
Dual · ACEARB-DUAL-02 · v2
When doctors add an ARB on top of an ACE inhibitor, the biggest head-to-head trials do not show that patients live longer. In high-risk vascular patients [1] and in people after a heart attack [4], the combination performed no better than a single drug on death and caused more side effects. A kidney-disease trial [8] and a large registry of advanced kidney patients [21] point the same way, the latter showing more deaths with dual therapy. The one clear exception is heart-failure patients with weak heart pumping, where adding candesartan to an ACE inhibitor lowered a measure that included cardiovascular death [3]. So the broad picture favours no survival gain from combining the two, but that heart-failure result keeps the claim from being read as universal.
The two largest direct combination-versus-monotherapy trials show no mortality advantage: ONTARGET [1] reports a combination relative risk of 0.99 (95% CI 0.92 to 1.07) on a composite that includes cardiovascular death, and VALIANT [4] reports a valsartan-plus-captopril hazard ratio of 0.98 (0.89 to 1.09, P=0.73) for death from any cause, both with more adverse events. VA NEPHRON-D [8] found no mortality benefit (hazard ratio for death 1.04, 0.73 to 1.49, P=0.75) and more harm in diabetic nephropathy, and Val-HeFT [2] found overall mortality similar. The observational Lin cohort [21] found higher death with dual therapy (HR 1.49, 1.30 to 1.71). Against this, CHARM-Added [3] found that adding candesartan to an ACE inhibitor in reduced-ejection-fraction heart failure cut a composite of cardiovascular death or heart-failure admission (HR 0.85, 0.75 to 0.96, p=0.011) and reduced each component significantly. The contested point: The division is CHARM-Added [3]: in heart failure with reduced ejection fraction, the combination reduced a cardiovascular-death-containing composite, directly cutting against a universal reading of the claim. It also matters that the strongest supporting trial, ONTARGET [1], measures a four-part composite rather than cardiovascular mortality in isolation, so the claim's exact endpoint is tested only indirectly there.
All 26 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
CHARM-Added [3] directly contradicts a universal reading: adding candesartan to an ACEi in HFrEF reduced each component of a composite defined as cardiovascular death or HF hospitalisation, so the combination DID reduce CV mortality in that population.
ONTARGET's primary outcome [1] is a four-component composite (CV death, MI, stroke, HF hospitalisation), so the RR 0.99 is not an isolated cardiovascular-mortality estimate; the strongest supporting trial tests the claim's exact endpoint only indirectly.
Where it remains uncertain. CHARM-Added [3] found the combination reduced a composite of cardiovascular death or heart-failure admission (HR 0.85, p=0.011) in HFrEF, so the claim cannot be read as universal.
Aleatory
Even the large trials carry sampling variation, e.g. ONTARGET's RR 0.99 spans 0.92 to 1.07 [1] and VALIANT's HR 0.98 spans 0.89 to 1.09 [4].
Epistemic
The strongest supporting trial [1] reports a four-part composite, not cardiovascular death alone, so the claim's exact endpoint is measured only indirectly.
The load-bearing papers from a corpus of 26, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Largest combination-vs-monotherapy RCT shows no reduction in a composite that includes death from cardiovascular causes.
“The combination of the two drugs was associated with more adverse events without an increase in benefit.”
Panel auditInternal validity: high · scope of inference: Patients with vascular disease or high-risk diabetes without heart failure.Key limitations: primary outcome is composite, not CV mortality alone · CV mortality not reported separately for combination
Adding an ARB to background therapy did not lower mortality.
“Overall mortality was similar in the two groups.”
Panel auditInternal validity: high · scope of inference: Patients with NYHA class II-IV chronic heart failure on background therapy.Key limitations: mortality is all-cause not CV-specific · combination harm signal is post hoc subgroup · background ACEi use not quantified in abstract
Post-MI trial with death as primary endpoint: combination does not reduce mortality vs ACEi monotherapy.
“Combining valsartan with captopril increased the rate of adverse events without improving survival.”
Panel auditInternal validity: high · scope of inference: Patients after acute MI complicated by LV dysfunction, heart failure, or both.Key limitations: primary endpoint is all-cause death not CV mortality alone
Counter-evidence: in HFrEF on an ACEi, adding an ARB reduced the components of a composite whose primary outcome is cardiovascular death or HF hospitalisation.
“Candesartan reduced each of the components of the primary outcome significantly, as well as the total number of hospital admissions for CHF.”
Panel auditInternal validity: high · scope of inference: Patients with NYHA II-IV CHF and LVEF 40% or lower already on ACE inhibitors.Key limitations: CV death not reported as a standalone number in abstract · primary outcome is composite of CV death or CHF hospitalization
4 of 26 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Large high-quality RCTs broadly support the null, but the HFrEF reduction in CHARM-Added [3] prevents a higher tier.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Reconciling the HFrEF exception. CHARM-Added [3] shows the combination reduced a cardiovascular-death-containing composite in reduced-ejection-fraction heart failure, cutting against a universal claim. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A dedicated ACEi+ARB trial in HFrEF reporting cardiovascular mortality separately, to establish whether the benefit is population-specific.
Open question: Does ACEi+ARB combination reduce cardiovascular mortality specifically in HFrEF, as CHARM-Added's composite suggests? Why it is still open: CHARM-Added [3] reports a composite reduction with each component reduced, but the corpus has no HFrEF trial isolating cardiovascular death, and the null-supporting trials enrolled other populations.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19